Halozyme Therapeutics | HALO - Vertriebs- Und Verwaltungskosten

Aktienkurs
65.36
Täglich Wechseln
-1.23 -1.85%
Monatlich
3.35%
Jährlich
8.05%
Q2 Prognose
63.96




Vertriebs- Und Verwaltungskosten Veränderung Datum
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amarin USD 18.97M 1.03M 2025-12
Amgen USD 1.94B 237M 2025-12
Baxter International USD 761M 53M 2025-12
Cara Therapeutics USD 2.19M 2.45M 2025-09
Cytokinetics USD 91.72M 67.02M 2025-12
DBV Technologies USD 3.63M 3.18M 2025-09
Eli Lilly USD 3.13B 391.3M 2025-12
Esperion Therapeutics USD 39.42M 456K 2025-12
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
Intrexon USD 10.31M 41K 2024-06
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
MannKind USD 29.09M 2.53M 2025-09
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Pfizer USD 4.08B 894M 2025-12
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
United Therapeutics USD 190.6M 38.6M 2025-12
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12